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Editorial on the Research Topic
Macrophages in Liver Disease
Macrophages constitute a key component of our immune system and play an important
role in immune surveillance. Hepatic macrophages are a heterogeneous population of
immune cells that mainly comprises of embryonically-derived resident Kupffer cells (KCs),
and circulating monocyte-derived macrophages (MoMFs). They play a critical role in
disease initiation and progression as well as contribute to disease resolution. Traditionally,
macrophages were defined by two broad subsets: classically-activated pro-inflammatory M1 or
alternatively-activated anti-inflammatory M2 macrophages. However, it has been recognized that
macrophages can differentiate into multiple phenotypes with distinct functions based on the
tissue microenvironment.
A review by van der Heide et al. summarizes the current understanding of the hepatic
macrophages, their diverse origins and phenotypes, and their role in maintaining homeostasis,
progression, as well as in the resolution of liver diseases. Furthermore, the review provides
a comprehensive overview of the therapeutic targeting strategies against hepatic macrophages
developed for the treatment of liver diseases. Blériot and Ginhoux further elaborated on
understanding the heterogeneity of hepatic macrophages. The review briefly discuss the intrinsic
and extrinsic factors including metabolic zonation and how they impact cellular phenotypes,
functions, and liver physiology. It further provides insights into the recent advances of
single-cell transcriptomic approaches, and how they contribute to decipher the liver macrophage
heterogeneity and biology.
Liver injury triggers the recruitment of extrahepatic monocytes that replenish the pool of
hepatic macrophages upon resident KCs depletion or damage. This heterogeneous population
of macrophages are involved in the pathogenesis of alcoholic liver disease (ALD), non-alcoholic
fatty liver disease (NAFLD), hepatitis B virus/hepatitis C virus (HBV/HCV), and hepatocellular
carcinoma (HCC). Dou et al. summarize current knowledge about the role of tissue-resident
and recruited macrophages in the pathogenesis of different etiological liver diseases. The review
further describes the existence of multiple macrophage origins and phenotypes, their identification
markers and roles in disease pathogenesis, and how this knowledge can be translated into future
therapies. Oates et al. highlight the landscape of mechanisms underlying macrophage dynamics,
macrophage interplay with other cells/tissues, and immunometabolism that collectively contribute
to NAFLD progression. Since macrophage-driven inflammation is intricately linked to various
metabolic pathways, the potential benefits to be gained from understanding the interplay between
metabolic and inflammatory pathways in macrophages are immense.
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In an original research article, Schierwagen et al. investigated
the involvement of macrophage-inducible C-type lectin (mincle),
expressed on macrophages, in different stages of chronic
liver disease (CLD). The authors showed increased mincle
expression that correlated with disease severity as examined
in rodent models of cirrhosis, non-alcoholic steatohepatitis
(NASH) and acute-on-chronic liver failure (ACLF), and in
patients with NASH and cirrhosis, and that undergoing bariatric
surgery. They further showed that mincle activation using
mincle agonist, trehalose-6,6-dibehenate, significantly increased
collagen production in ApoE-deficient high-fat Western diet-
induced NASH mouse model and further confirmed in cirrhosis
and ACLF animal models. These findings suggested that mincle
expressed on macrophages contribute to inflammation and
fibrosis, when the intestinal barrier becomes leaky, during
advanced stages of CLD. Macrophages (and innate immunity)
also play an important role in the pathogenesis of biliary atresia
(BA), a devastating cholangiopathy of infancy progressing to end-
stage liver disease often requiring liver transplantation. A review
by Ortiz-Perez et al. provides a comprehensive overview of BA
immunopathogenesis and the intricate mechanisms involved in
the disease pathogenesis. The authors further highlighted the
challenges such as lack of suitable experimental models that
hinder the deeper understanding of the disease, etiology, and
development of new therapies.
Hepatic macrophages interact with multiple cell types in
the liver including hepatocytes, cholangiocytes, hepatic stellate
cells (HSCs), liver sinusoidal endothelial cells (LSECs), platelets,
and other immune cells. A review by Shan and Ju describes
the impact of tissue microenvironmental factors that determine
the phenotype and function of hepatic macrophages, and the
crosstalk between hepatic macrophages and other hepatic cells,
in regulating the extents of liver injury, repair and disease
progression. For instance, macrophages secrete factors, can
physically interact with vasculature to assist the formation of
complex vascular networks, and activate HSCs and LSECs, and
promote fibrogenesis and angiogenesis, respectively. Conversely,
HSCs and LSECs (and other hepatic cells) secrete chemotactic
factors increasing intra-hepatic macrophage infiltration.
Ramirez-Pedraza and Fernández reviewed the molecular and
cellular crosstalk between macrophages and angiogenesis, and
provides detailed insights into the contribution of macrophages
to liver steatosis, fibrosis, cirrhosis, HCC, and extrahepatic
complications. Targeting angiogenesis-inflammation axis
therefore can be an interesting approach for the treatment of
liver diseases.
Macrophages also play a central role in keeping the balance
of immunity and tolerance. During early HCC development,
fibro-inflammation driven by pro-inflammatory macrophages
(and HSCs) provide a microenvironment permissive for tumor
initiation, while at advanced HCC, macrophage switching
to immunosuppressive tumor-associated macrophages (TAMs)
support tumor progression and malignancy. The crosstalk
between tumor cells (the “seeds”) and microenvironment (the
“soil”) play an important role in tumor development and
metastasis. A review by Sällberg and Pasetto focuses on
macrophages and other key cellular components of the liver
and tumor microenvironment, their role in controlling the
balance between tolerance and activation, and the potential
therapeutic interventions to tilt the balance against liver
cancer progression. Hepatic macrophages, particularly KCs, are
essential for maintaining homeostasis by scavenging bacteria and
cellular debris, and thereby induce immunological tolerance. An
inefficient efferocytosis mechanism impairing the clearance of
cellular debris results in subsequent loss of tissue homeostasis.
Horst et al. describe how efferocytosis in hepatic macrophages
regulate tissue homeostasis and regeneration in liver diseases.
It is essential to understand the tempo-spatial contribution
of macrophages and efferocytosis mechanisms in different
etiological liver diseases, for the development of potential
interventions against liver diseases.
Besides efferocytosis, macrophages facilitate resolution of liver
fibrosis [characterized by excessive accumulation of extracellular
matrix (ECM) proteins] by producing matrix-degrading
enzymes (matrix metalloproteinases, MMPs) that degrade
fibrotic ECM. Upon liver damage, macrophages induce HSCs
trans-differentiation into proliferative, fibrogenic myofibroblasts
that secrete large amounts of ECM proteins, predominantly
fibrillar collagens, and ECM crosslinking enzymes, lysyl oxidase-
like 2 (LOXL2), that stabilize ECM components. Klepfish et al.
demonstrated that a novel anti-LOXL2 monoclonal antibody
(GS341) ameliorated liver fibrosis in vivo. Mechanistically,
anti-LOXL2 antibody inhibited LOXL2-mediated collagen
crosslinking and facilitated the recruitment of so-called scar-
associated MoMFs (SAMs) expressing a unique repertoire of
collagenolytic MMPs (in particular MMP-14) to the proximity of
collagenous fibrotic fibers. These findings suggest that therapies
augmenting the recruitment of collagenolytic macrophages
and/or polarization of macrophages into collagenolytic
macrophages might be an interesting approach to reverse
fibrosis and facilitate endogenous liver regeneration.
MoMFs recruitment is regulated by monocyte chemotactic
protein 1 (MCP-1 or CCL2). Queck et al. investigated
intrahepatic expression and circulating levels of MCP-1, and
its correlation with monocyte infiltration and severity of liver
diseases. Using rodent models of liver cirrhosis and ACLF,
authors showed an elevated hepatic expression of CCL2 along
with increased F4/80-positivemacrophages in the liver. In human
liver explants and ACLF patients, hepatic transcription levels
of CCL2 correlated with the MELD score, and higher portal
and hepatic vein levels of MCP-1 correlated with Child-Pugh
score, respectively. This study concluded that MCP-1 circulating
levels, derived from the injured liver, reflect the intra-hepatic
macrophages and correlate with severity of liver disease.
An interesting review by Shwartz et al. describes an emergence
of the teleost zebrafish, an attractive new vertebrate model to
study liver macrophages. Authors summarize the origin and
functions of macrophages in the livers of zebrafish models of
ALD, NAFLD, HCC, and liver regeneration. The review discusses
how macrophages in zebrafish models can be compared with
that described in mammals and highlights the advantages and
challenges of using zebrafish models to study liver macrophages.
Colino et al. summarizes the different types of passive
(driven by anatomical and physiological features) and
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active (using specific ligands) targeted nanoparticle (NP)
systems for macrophage recognition and drug targeting. To
design NPs, NPs biocompatibility, degradability, toxicity,
in vivo pharmacokinetics and drug release should be
contemplated. Furthermore, recognition mechanisms
by macrophages must be investigated considering the
changes in the microenvironment that can influence the
macrophage phenotype and impact NPs uptake. The authors
further present the physiological-based pharmacokinetic
(PBPK) model to characterize the biodistribution
of NPs.
Altogether, this special issue presents a series of 9
reviews, 2 mini-reviews, and 3 original articles focusing on
the understanding of macrophages and/or innate immune
system in liver diseases. It also highlights the intricacies
of distinct macrophage phenotypes at different stages
of the diverse etiological liver diseases and provides a
comprehensive overview of the therapeutic targets and
macrophages targeting approaches for the treatment of
liver diseases.
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